A Phase II Study to Compare the Safety and Efficacy of Direct Oral Anticoagulants versus Subcutaneous Dalteparin for Cancer-Associated Venous Thromboembolism in Patients with Advanced Upper Gastrointestinal, Hepatobiliary and Pancreatic Cancer: PRIORITY.

Cancers (Basel) · 2022 · PMC8833795 · PMID 35158827

Europe PMC DOI

hedged sentence

0.1040

closest p · 2.1× alpha

0.1040

boldest claim

The sentences

showed a trendp = 0.104not close (p > 0.1)

In terms of the time to MB or CRB, rivaroxaban showed a trend of being a risk factor for MB (HR 3.89; p = 0.104) and CRB (HR 2.37; p = 0.102) compared to dalteparin ( Table S2 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.